Xeris Pharmaceuticals Stock Buy Hold or Sell Recommendation
| XERS Stock | USD 3.09 0.05 1.64% |
Given the investment horizon of 90 days and your conservative risk appetite, our recommendation regarding Xeris Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Xeris Pharmaceuticals given historical horizon and risk tolerance towards Xeris Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Xeris Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Xeris Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Xeris and provide practical buy, sell, or hold advice based on investors' constraints. Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Xeris |
Execute Xeris Pharmaceuticals Buy or Sell Advice
The Xeris recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Xeris Pharmaceuticals. Macroaxis does not own or have any residual interests in Xeris Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Xeris Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Xeris Pharmaceuticals Trading Alerts and Improvement Suggestions
| Xeris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 163.91 M. Net Loss for the year was (62.26 M) with profit before overhead, payroll, taxes, and interest of 87.61 M. | |
| Xeris Pharmaceuticals currently holds about 111.55 M in cash with (47.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82. | |
| Xeris Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Piper Sandler cuts Xeris Pharma stock to Neutral, despite top-line progress - Investing.com |
Xeris Pharmaceuticals Returns Distribution Density
The distribution of Xeris Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Xeris Pharmaceuticals' future price movements. The chart of the probability distribution of Xeris Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Xeris Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Xeris Pharmaceuticals returns is essential to provide solid investment advice for Xeris Pharmaceuticals.
| Mean Return | 0.18 | Value At Risk | -4.42 | Potential Upside | 4.30 | Standard Deviation | 2.62 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Xeris Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Xeris Stock Institutional Investors
The Xeris Pharmaceuticals' institutional investors refer to entities that pool money to purchase Xeris Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 1.3 M | Aqr Capital Management Llc | 2024-06-30 | 1.2 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Redmile Group, Llc | 2024-09-30 | 1 M | D. E. Shaw & Co Lp | 2024-09-30 | 985 K | Bank Of America Corp | 2024-06-30 | 641.7 K | Lazard Asset Management Llc | 2024-06-30 | 636.2 K | Kennedy Capital Management Inc | 2024-09-30 | 604.9 K | Tudor Investment Corp Et Al | 2024-09-30 | 507.4 K | Blackrock Inc | 2024-06-30 | 10.3 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
Xeris Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.2M) | (5.1M) | (7.4M) | (7.5M) | (14.8M) | (14.1M) | |
| Investments | (102.5M) | (101.8M) | 60.6M | 34.5M | (6.0M) | (6.3M) | |
| Change In Cash | (26.2M) | 18.1M | 29.7M | 59.0M | (54.6M) | (51.9M) | |
| Free Cash Flow | (105.5M) | (80.9M) | (96.6M) | (103.4M) | (49.3M) | (51.8M) | |
| Depreciation | 1.1M | 1.5M | 1.9M | 12.7M | 13.2M | 13.8M | |
| Other Non Cash Items | 948K | 3.1M | 961K | 3.5M | (1.1M) | (1.0M) | |
| Capital Expenditures | 1.1M | 377K | 1.1M | 524K | 2.3M | 2.4M | |
| Net Income | (125.6M) | (91.1M) | (122.7M) | (94.7M) | (62.3M) | (65.4M) | |
| End Period Cash Flow | 19.5M | 37.6M | 67.3M | 126.3M | 71.7M | 60.8M | |
| Change To Netincome | 6.5M | 8.3M | 12.5M | 12.7M | 14.6M | 15.3M |
Xeris Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Xeris Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Xeris Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Xeris stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.02 | |
β | Beta against Dow Jones | 1.28 | |
σ | Overall volatility | 2.64 | |
Ir | Information ratio | 0.02 |
Xeris Pharmaceuticals Volatility Alert
Xeris Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Xeris Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Xeris Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Xeris Pharmaceuticals Fundamentals Vs Peers
Comparing Xeris Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Xeris Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Xeris Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Xeris Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Xeris Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Xeris Pharmaceuticals to competition |
| Fundamentals | Xeris Pharmaceuticals | Peer Average |
| Return On Equity | -6.17 | -0.31 |
| Return On Asset | -0.087 | -0.14 |
| Profit Margin | (0.34) % | (1.27) % |
| Operating Margin | (0.24) % | (5.51) % |
| Current Valuation | 662.22 M | 16.62 B |
| Shares Outstanding | 149.08 M | 571.82 M |
| Shares Owned By Insiders | 3.90 % | 10.09 % |
| Shares Owned By Institutions | 43.83 % | 39.21 % |
| Number Of Shares Shorted | 11.37 M | 4.71 M |
| Price To Book | 3.34 X | 9.51 X |
| Price To Sales | 2.46 X | 11.42 X |
| Revenue | 163.91 M | 9.43 B |
| Gross Profit | 87.61 M | 27.38 B |
| EBITDA | (23.73 M) | 3.9 B |
| Net Income | (62.26 M) | 570.98 M |
| Cash And Equivalents | 111.55 M | 2.7 B |
| Cash Per Share | 0.82 X | 5.01 X |
| Total Debt | 229.19 M | 5.32 B |
| Debt To Equity | 1.87 % | 48.70 % |
| Current Ratio | 2.50 X | 2.16 X |
| Book Value Per Share | (0.19) X | 1.93 K |
| Cash Flow From Operations | (47.02 M) | 971.22 M |
| Short Ratio | 9.52 X | 4.00 X |
| Earnings Per Share | (0.43) X | 3.12 X |
| Target Price | 4.77 | |
| Number Of Employees | 377 | 18.84 K |
| Beta | 1.29 | -0.15 |
| Market Capitalization | 460.66 M | 19.03 B |
| Total Asset | 322.6 M | 29.47 B |
| Retained Earnings | (617.02 M) | 9.33 B |
| Working Capital | 61.07 M | 1.48 B |
| Net Asset | 322.6 M |
Note: Disposition of 5784 shares by Hecht Beth of Xeris Pharmaceuticals at 1.24 subject to Rule 16b-3 [view details]
Xeris Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Xeris . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Xeris Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Xeris Pharmaceuticals? Buying financial instruments such as Xeris Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Xeris Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.